TWI471322B - 新穎醯胺衍生物及其作為醫藥之用途 - Google Patents

新穎醯胺衍生物及其作為醫藥之用途 Download PDF

Info

Publication number
TWI471322B
TWI471322B TW98136276A TW98136276A TWI471322B TW I471322 B TWI471322 B TW I471322B TW 98136276 A TW98136276 A TW 98136276A TW 98136276 A TW98136276 A TW 98136276A TW I471322 B TWI471322 B TW I471322B
Authority
TW
Taiwan
Prior art keywords
group
substituent
carbon atoms
carbon number
carbon
Prior art date
Application number
TW98136276A
Other languages
English (en)
Chinese (zh)
Other versions
TW201024290A (en
Inventor
Seigo Ishibuchi
Hidemasa Hikawa
Akiko Tarao
Jun-Ichi Endoh
Kunitomo Adachi
Kazuhiro Maeda
Kaoru Tashiro
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of TW201024290A publication Critical patent/TW201024290A/zh
Application granted granted Critical
Publication of TWI471322B publication Critical patent/TWI471322B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW98136276A 2008-10-27 2009-10-27 新穎醯胺衍生物及其作為醫藥之用途 TWI471322B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008276147 2008-10-27

Publications (2)

Publication Number Publication Date
TW201024290A TW201024290A (en) 2010-07-01
TWI471322B true TWI471322B (zh) 2015-02-01

Family

ID=42128822

Family Applications (1)

Application Number Title Priority Date Filing Date
TW98136276A TWI471322B (zh) 2008-10-27 2009-10-27 新穎醯胺衍生物及其作為醫藥之用途

Country Status (15)

Country Link
US (1) US8354401B2 (fr)
EP (1) EP2364975B1 (fr)
JP (1) JP5478499B2 (fr)
KR (1) KR101712679B1 (fr)
CN (1) CN102239152B (fr)
AU (1) AU2009310952B2 (fr)
CA (1) CA2741661C (fr)
DK (1) DK2364975T3 (fr)
ES (1) ES2427397T3 (fr)
MX (1) MX2011004372A (fr)
PL (1) PL2364975T3 (fr)
PT (1) PT2364975E (fr)
RU (1) RU2487124C2 (fr)
TW (1) TWI471322B (fr)
WO (1) WO2010050461A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058766A1 (fr) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Dérivés d'arylcarboxamide comme bloqueurs de ttx-s
JP2011246461A (ja) * 2010-04-27 2011-12-08 Mitsubishi Tanabe Pharma Corp 新規アミド誘導体を含有する医薬組成物
DK2565182T3 (en) * 2010-04-27 2017-12-04 Mitsubishi Tanabe Pharma Corp New amide derivative and its use as a drug
JP5800786B2 (ja) * 2011-10-26 2015-10-28 田辺三菱製薬株式会社 新規アミド誘導体を有効成分として含有する医薬組成物
WO2013134079A1 (fr) 2012-03-05 2013-09-12 Amgen Inc. Composés d'oxazolidinone et leurs dérivés
CN104995173A (zh) 2012-11-30 2015-10-21 协和发酵麒麟株式会社 含氮杂环化合物
CN104262238B (zh) * 2014-08-29 2016-08-03 西安交通大学 一种芳杂环联苯类Bcr-Abl抑制剂及其制备方法和应用
CN107108573B (zh) 2014-10-24 2020-06-16 朗多生物制药股份有限公司 基于羊毛硫氨酸合成酶c样2的治疗剂
KR20180041662A (ko) * 2015-07-09 2018-04-24 미쓰비시 타나베 파마 코퍼레이션 신규 이미드 유도체 및 그 의약으로서의 용도
CN113316571A (zh) * 2018-11-14 2021-08-27 阿林齐生物制药公司 用于治疗白细胞介素1β相关病症的吡啶磺酰胺化合物
WO2021127472A1 (fr) 2019-12-20 2021-06-24 Landos Biopharma, Inc. Ligands de la protéine 2 de type lanthionine c, cellules préparées avec ceux-ci, et thérapies les utilisant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1433413A (zh) * 2000-06-05 2003-07-30 东亚制药株式会社 新的噁唑烷酮衍生物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US6638952B1 (en) * 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
CN1253474A (zh) * 1997-03-04 2000-05-17 孟山都公司 磺酰基二价芳基或杂芳基异羟肟酸化合物
US6750228B1 (en) * 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JP2003321368A (ja) * 2002-04-30 2003-11-11 Azwell Inc Ｎ，ｎ’−ジ置換ウレアまたはチオウレア化合物含有医薬
JP4480128B2 (ja) 2002-11-20 2010-06-16 独立行政法人科学技術振興機構 マトリックスメタロプロテアーゼ−９の産生を阻害するための薬剤
AU2003202753A1 (en) * 2003-02-07 2004-08-30 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
RU2351335C2 (ru) * 2003-04-30 2009-04-10 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Применение оксазолидинон-хинолиновых гибридных антибиотиков для лечения сибирской язвы и других инфекций
ZA200509147B (en) * 2003-04-30 2007-03-28 Morphochem Ag Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections
ES2310299T5 (es) 2003-12-18 2014-02-10 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibióticos híbridos a base de oxazolidinona-quinolona
MX2007009946A (es) * 2005-02-16 2007-09-26 Schering Corp Piperazin-piperidinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3.
JP5760248B2 (ja) * 2006-09-12 2015-08-05 国立大学法人東京農工大学 腫瘍の骨転移抑制および／または予防剤
JP2008276147A (ja) 2007-04-02 2008-11-13 Seiko Epson Corp 現像装置、画像形成装置、及び、画像形成システム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1433413A (zh) * 2000-06-05 2003-07-30 东亚制药株式会社 新的噁唑烷酮衍生物及其制备方法

Also Published As

Publication number Publication date
DK2364975T3 (da) 2013-09-08
RU2011121362A (ru) 2012-12-10
JPWO2010050461A1 (ja) 2012-03-29
WO2010050461A1 (fr) 2010-05-06
AU2009310952B2 (en) 2015-04-30
EP2364975B1 (fr) 2013-06-12
EP2364975A4 (fr) 2012-05-02
KR101712679B1 (ko) 2017-03-22
KR20110081312A (ko) 2011-07-13
US8354401B2 (en) 2013-01-15
CN102239152A (zh) 2011-11-09
AU2009310952A1 (en) 2010-05-06
TW201024290A (en) 2010-07-01
ES2427397T3 (es) 2013-10-30
PL2364975T3 (pl) 2013-12-31
PT2364975E (pt) 2013-09-09
CN102239152B (zh) 2014-10-29
US20110263571A1 (en) 2011-10-27
CA2741661A1 (fr) 2010-05-06
CA2741661C (fr) 2016-12-13
RU2487124C2 (ru) 2013-07-10
MX2011004372A (es) 2011-05-23
EP2364975A1 (fr) 2011-09-14
JP5478499B2 (ja) 2014-04-23

Similar Documents

Publication Publication Date Title
TWI471322B (zh) 新穎醯胺衍生物及其作為醫藥之用途
TWI794297B (zh) 化合物用於製備與第二抗-呼吸道融合性病毒試劑組合使用以治療呼吸道細胞融合病毒感染的藥物之用途及醫藥組合物
CN112135825A (zh) 血浆激肽释放酶抑制剂及其用途
CN104693193B (zh) 芳基甲氧基异吲哚啉衍生物和包括其的组合物及它们的使用方法
JP6117430B2 (ja) 選択的ヒストン脱アセチル化酵素抑制剤としての新規化合物およびこれを含む薬剤学的組成物
CN103987707B (zh) 吡唑‑4‑基‑杂环基‑甲酰胺化合物以及使用方法
CN106414429B (zh) 吡唑化合物及其作为t型钙通道阻断剂的用途
CN114650868A (zh) Helios的小分子降解剂及其使用方法
CN114728962A (zh) 血浆激肽释放酶抑制剂及其用途
CN108348523A (zh) 包含pi3k抑制剂和hdac抑制剂的组合物
CN106456609A (zh) 作为irak4抑制剂的取代的吲唑化合物
WO2011086531A2 (fr) Nouveaux agents antipaludiques
CN103415289A (zh) 前神经原性化合物
CN109310679A (zh) 包含组蛋白脱乙酰酶抑制剂的组合
JP6779899B2 (ja) Ｔｎｆ阻害剤として有用なヘテロ環式化合物
KR102633911B1 (ko) 9원 축합환 유도체
CN103459382B (zh) 用于抑制pask的杂环化合物
WO2023217232A1 (fr) Inhibiteur de kinésine kif18a et son utilisation
CN104364246A (zh) 用作gpr119激动剂的哌啶衍生物
TW202130631A (zh) ３—（５—甲氧基—１—側氧基異吲哚啉—２—基）哌啶—２，６—二酮衍生物及其用途
JP2020532589A (ja) Ｉｒｅ１阻害のための化合物および組成物
CN102971291A (zh) 新型酰胺衍生物及其作为药物的用途
JP2022502370A (ja) 置換ピリジニル化合物およびその使用
CN111315734A (zh) 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物
CN114667289A (zh) 杂芳基血浆激肽释放酶抑制剂

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees